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Abstract
We aimed to investigate the impact of the single nucleotide polymorphisms of rs34436714 of the NOD-like receptor protein 12 gene
on the production of tumor necrosis factor-alpha (TNFa) in patients with inﬂammatory bowel disease (IBD)
In a matched case-control study 90 patients with IBD, 56 with Crohn disease (CD) and 34 with ulcerative colitis, were genotyped
and compared to 98 healthy comparators matched for age and gender. Expression level of TNFa, interleukin (IL)-6, IL-12, and soluble
triggering receptor expressed on myeloid cells were measured in patients’ sera. Peripheral blood mononuclear cells (PBMCs) were
isolated and stimulated for TNFa production.
Serum TNFa was greater among carriers of GT/TT genotypes than GG genotypes of rs34436714. Stimulated TNFa production
was also higher in carriers of GT/TT genotypes. The frequency of CD with ﬁstulizing behavior and with CD involving the small intestine
was greater among carriers of GT/TT genotypes than of the GG genotype. Distribution of the GG, GT, and TT genotypes of
rs34436714 were in Hardy–Weinberg equilibrium in both groups. The genotype distribution was the same in both groups.
Carriage of minor frequency alleles of rs34436714 was accompanied by greater circulating levels of TNFa and by greater capacity
for stimulated TNFa production by PBMCs. These alleles had an impact on the phenotype of patients with CD.
Abbreviations: CD = Crohn disease, IBD = inﬂammatory bowel disease, IL = interleukin, LPS = lipopolysaccharide, NLRP12 =
NOD-like receptor protein 12, NOD = nucleotide binding domain, PBMCs = peripheral blood mononuclear cells, SNP = single
nucleotide polymorphism, sTREM-1 = soluble triggering receptor expressed on myeloid cells-1, TNFa = tumor necrosis factor-
alpha, UC = ulcerative colitis.
Keywords: inﬂammatory bowel disease, NLRP12, single nucleotide polymorphisms, TNFa
1. Introduction
The interaction of gut microbiota with tissue macrophages is
more and more recognized as a key component in the
pathogenesis of inﬂammatory bowel disease (IBD). This interac-
tion is mediated by the recognition of pathogen-associated
patterns of bacterial ﬂora by the nucleotide binding domain
(NOD)-like intracellular receptors of macrophages. Carriage of
single nucleotide polymorphisms (SNPs) in any of these receptors
may modulate the susceptibility of the host for the development
of IBD.[1]
One well-recognized receptor is NOD-like receptor protein 12
(NLRP12). NLRP12 is associated with the protein adaptor ASC
inducing the formation of an active IL-1b maturing inﬂamma-
some.[2] It also acts as a negative regulator of pro-inﬂammatory
cytokine production via inhibition of non-canonical NF-kB
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activation.[3] The NLRP12 has been shown to play a role in the
maintenance of intestinal homeostasis and protection against
tumorigenesis in animal models.[4] Recent data revealed
decreased expression of NLRP12 in patients with active
ulcerative colitis (UC) as compared to healthy controls and
patients with inactive UC.[5] Since NLRP12 is a negative
regulator of inﬂammation, it may be hypothesized that it also
downregulates the production of tumor necrosis factor-alpha
(TNFa). TNFa is recognized as a key molecule in the
pathogenesis of IBD and factors affecting its production may
participate in pathogenesis.
NLPR12 is located on chromosome 19. One common SNP of
NLRP12 is rs34436714 where guanine is substituted by thymine
leading to the missense substitution of glycine by valine. Taking
into consideration the above described role of NLRP12 to
downregulate inﬂammation in the gut and the lower NLRP12
expression among patients with IBD, we questioned if carriage of
SNP alleles of rs34436714 may modulate the production of
TNFa.
2. Patients and methods
2.1. Study design
This was a case-control study of patients with IBD and healthy
comparators. The study was approved by the Ethics Committee
of the ATTIKON University Hospital, in Athens, Greece.
Inclusion criteria for patients were:
(1) Caucasian origin;
(2) age equal to or above 18 years;
(3) both genders;
(4) written informed consent provided by the patients; and
(5) diagnosis of IBD with clinical, endoscopic, and histological
documentation.
Inclusion criteria for the comparators were to be of the same
age and gender and to provide written informed consent as the
patients and not to have any known chronic disorder. Exclusion
criteria were:
(1) age below 18 years;
(2) denial to consent;
(3) any other chronic inﬂammatory disorder;
(4) infection by the human immunodeﬁciency virus;
(5) chronic hepatitis B or C; and
(6) any fungal infection.
Ten millilitres of peripheral blood was sampled from each
patient or comparator after venipuncture of the forearm vein
under aseptic conditions; 5ml were collected into EDTA-coated
tubes (Vacutainer, BD) to isolate genomic DNA by standard
methods; another 5ml were collected into sterile and clean tubes
free of anticoagulant. After centrifugation, serum was stored at
80°C until assayed.
Genomic DNA was isolated from whole blood using standard
procedures. The genotype for the NLRP12 polymorphism
rs34436714 in the patients was screened by the TaqMan SNP
assay C_25927410_10, on the 7300 ABI Real-Time polymerase
chain reaction system (Applied Biosystems, CA).
In 1 out of 5 patients, another 20ml of whole blood was
sampled and collected into heparinized tubes. Peripheral blood
mononuclear cells (PBMCs) were isolated after gradient
centrifugation over Ficoll (Merck, Darmstadt, Germany). After
3 consecutive washings in ice-cold phosphate buffered saline (pH:
7.2), PBMCs were counted in a Neubauer chamber with trypan
blue exclusion of dead cells. Cells were distributed in duplicate in
wells of 96-well plates and incubated at a density of 5106/ml
without/with 10ng/ml of lipopolysaccharide (LPS) of Escherichia
coli O55:B5 (Sigma, St. Louis). The growth medium was
RPMI1640 enriched with 5% glutamate (Merck). Plates were
incubated for 24hours at 37°C in 5% CO2 atmosphere. At the
end of the incubation plates were centrifuged and supernatants
were collected and stored at 80°C until assayed for TNFa.
TNFa, interleukin (IL)-6, IL-12, and soluble triggering receptor
expressed on myeloid cells-1 (sTREM-1) were measured in serum
and supernatants of patients by an enzyme immunosorbent assay
according to the instructions of the manufacturer (R&D Inc,
Minneapolis). The lower limit of detectionwas5.6pg/ml for TNFa
and IL-6; 31.3pg/ml for IL-12; and 15.1pg/ml for sTREM-1.
The primary study endpoint was the impact of the genotype of
rs34436714 on TNFa levels. Secondary study endpoints were:
(1) the impact of the genotype of rs34436714 on the other
measured serum cytokines;
(2) the impact of the genotype of rs34436714 on the clinical
characteristics of Crohn disease (CD); and
(3) the difference in genotype distribution of rs34336714
between patients and comparators.
2.2. Study power
The study was powered for the primary endpoint. It was
hypothesized that
(1) 30% of patients would be carriers of at least 1 minor
frequency allele and 70% of patients of major frequency
alleles; and
(2) the mean difference of serum TNFa would be 50pg/ml and
the standard deviation would vary by 70pg/ml.
In order to demonstrate this difference at the 10% level of
signiﬁcancewith 80%power at least 80 patients should be enrolled.
2.3. Statistical analysis
Cytokine concentrations were expressed as means±SE and
compared by the Mann–Whitney U test. Genotype and allele
distribution were expressed as frequencies and compared by the
Fisher exact test. Any value of P below .05 was considered
signiﬁcant.
3. Results
A total of 90 patients with IBD, 34 with UC and 56 with CD, and
98 healthy comparators were enrolled. The study ﬂow chart is
shown in Figure 1. The demographics of patients and
comparators are provided in Table 1.
The primary study endpoint was the modulation of TNFa by
SNPs of rs34436714. As it can be seen in Figure 2A, circulating
concentrations of TNFa were greater among patients carrying at
least 1 T allele of rs34436714. In order to elaborate this further,we
isolated PBMCs from 20 patients, 10 with UC and 10 with CD.
After stimulationwith bacterial LPS, PBMCsof patients carryingT
alleles of rs34436714 produced more TNFa than PBMCs of
patients carrying only the major frequency allele (Fig. 2B).
However, it is suggested that treatmentwith chemical or biological
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disease responsemodiﬁers maymodulate the ability of the host for
TNFa production.[6] To this end, circulating concentrations of
TNFawere compared separately between patients carrying major
andminor frequency alleles of rs34436714 in relation to treatment
with at least 1 drug and with at least 2 or more drugs. Circulating
TNFa was greater among patients under treatment with 2 or 3
drugs who were carriers of at least 1 minor frequency T allele of
rs34436714 (Fig. 2C).
Expression levels of sTREM-1, IL-6, and IL-12 did not differ
between carriers of at least 1 T allele of rs34436714 and carriers
of only major frequency alleles (Fig. 3).
We hypothesized that carriage of minor frequency T alleles that
was associated with greater production capacity for TNFamight
also be associated with the clinical phenotypes of CD. Analysis
showed that carriage of GT and TT genotypes was associated
with greater frequency of CD with ﬁstulizing behavior (Fig. 4A)
and with CD located only at the small intestine (Fig. 4B).
Among the comparators, 66 (67.3%), 28 (29.5%), and 4
(4.1%) hadGG, GT, and TT genotypes, respectively. Among IBD
patients, 59 (65.6%), 28 (31.1%), and 3 (3.3%) had GG, GT,
and TT genotypes, respectively. No deviation from Hardy–
Weinberg equilibrium was detected in either comparators (HWE:
0.01; P: .976) or patients (HWE: 0.02; P: .884). No difference in
the genotype distribution was found between patients and
comparators (P: .907); 81.6% (n=160) of comparators were
carriers of major frequency G alleles and 18.4% (n=36) were
carriers of minor frequency T alleles; this distribution was 81.8%
(n=146) and 80.2% (n=34), respectively among patients.
4. Discussion
Our study shows how patients suffering with IBD who are
carrying minor frequency T alleles of rs34436714 of NLRP12
have greater circulating levels of TNFa and greater potential for
the production of TNFa after PBMCs stimulation. It also shows
how carriage of these alleles may have an impact on the
phenotype of patients with CD.
Figure 1. Study ﬂow chart. IBD= inﬂammatory bowel disease, PBMCs=
peripheral blood mononuclear cells.
Table 1
Demographic and clinical characteristics of patients enrolled in the study.
Ulcerative colitis (n=34) Crohn disease (n=56) Healthy comparators (n=98)
Male gender (n, %) 18 (52.9) 20 (35.7) 45 (45.9)
Age, yr (mean±SD) 49.5±17.2 42.3±18.9 43.5±17.8
History of operation (n, %) 2 (5.9) 19 (33.9)
Extraintestinal manifestations (n, %) 2 (5.9) 12 (21.4)
Extent of GI involvement (n, %)
Up to sigmoid 4 (11.8)
Pancolitis 30 (88.2) 11 (19.6)
Colon and terminal ileum 8 (14.3)
Colon and small intestine 16 (28.6)
Terminal ileus only 9 (16.1)
Small intestine only 12 (21.4)
Behavior (n, %)
Inﬂammatory 0 29 (51.8)
Fibrostenotic 0 12 (21.4)
Fistulizing 0 15 (26.8)
Activity
∗
(n, %)
Nonactive 19 (55.9) 40 (71.4)
Mild 8 (23.5) 5 (8.9)
Moderate 4 (11.8) 7 (12.5)
Severe 3 (8.8) 4 (7.1)
Medications (n, %)
5-amino salicylate 28 (82.4) 16 (28.6)
Immunosuppressants† 9 (26.5) 19 (33.9)
Anti-TNFs‡ 0 20 (35.7)
Corticosteroids 2 (5.9) 11 (19.6)
TNF= tumor necrosis factor alpha, SD = standard deviation.
∗
Mayo score for ulcerative colitis and Harvey–Bradshaw score for Crohn disease.
† Azathrioprine or cyclosporine.
‡ Inﬂiximab or adalimumab.
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Figure 2. Impact of rs34436714 genotype of NLRP12 on TNFa. Results are provided for (A) serum TNFa; (B) production of TNFa by PBMCs of patients after
stimulation with bacterial lipopolysaccharide; and (C) serum TNFa in relation to the intake of disease-modifying drugs (see Table 1). P values refer to the indicated
statistical comparisons. Production of TNFa by PBMCs without stimulation was below the limit of detection. NLRP12 = NOD-like receptor protein 12, PBMCs=
peripheral blood mononuclear cells, TNFa = tumor necrosis factor-alpha.
Figure 3. Serum concentrations of sTREM-1 and of IL-6 and -12 in relation to the rs34436714 genotype of NLRP12 P values refer to the indicated statistical
comparisons. IL = interleukin, NLRP12 = NOD-like receptor protein 12, sTREM-1 = soluble triggering receptor expressed on myeloid cells-1.
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A thorough literature search identiﬁed few studies on the
impact of the function of NLRP12 gene for the pathogenesis of
IBD. To our knowledge there is only clinical study trying to
investigate the role of the expression of NLRP12 in IBD: in a
paired comparison that involved 10 pairs of monozygotic UC
twins, healthy twins, and 7 UC patients, gene-proﬁling showed
reduced expression of NLRP12 in active UC.[5] However, the
role of rs34436714 was not explored.
Our results point towards an impact of SNPs of rs34436714 on
the production of TNFa. Indeed, IBD has been associated with
increased expression of TNFa in intestinal tissues.[7,8] The lack of
measurements of TNFa in at the gut tissue level may, at ﬁrst
glance, appear as a limitation of our study. However, 2 points
may be argued to strengthen the impact of the analyzed SNPs of
rs34436714 on TNFa expression as performed in this study
through the use of serum TNFa measurements:
(1) increased serum TNFa has been described by others in
patients with IBD[8,9]; and
(2) carriage of minor frequency T alleles of rs34436714 was
associated with greater serum TNFa but not with other
circulating cytokines.
This is in accordance with the current knowledge that IBD is a
disease hallmarked by elevated TNFa[10] but not by elevated IL-6
and IL-12.
It has been shown that circulating monocytes of patients with
CD produce more TNFa than healthy volunteers or patients with
UC.[11] Although it is anticipated that greater production of
TNFa may be associated with the behavior of CD and
refractoriness to treatment, such data are not published. To this
end, only indirect evidence is available. More precisely, it has
been shown in patients with IBD that carriage of minor frequency
A alleles at the -308 gene position increases by 6- to 7-fold the
gene transcription of TNFa and the subsequent TNFa deposition
at the tissue level. This inﬂuences the behavior of CD towards less
steroid-dependent disease.[12–14] To this end, it was interesting to
ﬁnd that carriage of minor frequency T alleles of rs34436714 that
are associated with elevated circulating TNFa and with high
stimulated production of TNFa by PBMCs was also associated
with the behavior of CD and with response to treatment. These
carriers presented commonly with CD with ﬁstulizing behavior
involving the small intestine and necessitated 2 or 3 drugs.
Although this may be considered of importance from a
pharmacogenomics perspective, a recent genome-wide associa-
tion study of 359 patients using the Illumina immunochip and
covering 196,524 SNPs did not report any association between
durability of response to anti-TNFs and rs34436714.[15]
The production of TNFa in the gut is stimulated by microbiota
where NLRP12 may function as a modulator. This is supported
by studies describing NLRP12 as an antagonist of pro-
inﬂammatory signals induced by Toll-like receptor ligands and
Mycobacterium tuberculosis[16] and downregulation of TLR-
dependent NFkB after gene silencing ofNLRP12.[3] The diversity
of gut microbiota is decreased when mice that are deﬁcient for
NLRP12 become obese after being fed high-fat diet; this is
associated with greater systemic inﬂammation.[17] Similar
ﬁndings were shown in mice subject to experimental colitis.[5]
The increased production of sTREM-1 that was found in the
IBD patients of our study is in agreement with the ﬁndings of 1
previous study of our group that identiﬁed sTREM-1 as a
mediator in IBD positively correlated with IBD activity.[18]
Despite the elevation of sTREM-1 in CD, this was not affected by
the carriage of minor frequency alleles of NLRP12. This
outscores the importance of the pathway linking NLRP12 to
TNFa and not to other pro-inﬂammatory mediators.
The small study population is also a limitation of our study.
However, the primary endpoint, that is, the association of serum
TNFa with the carriage of minor frequency T alleles of
re34436714 was shown even under that limitation.
Our ﬁndings showed that carriage of minor frequency alleles of
rs34436714 ofNRLP12was accompanied by greater circulating
levels of TNFa and by greater capacity for stimulated TNFa
production by PBMCs. These alleles had an impact on the
phenotype of patients with CD. Although our results pinpoint
some signiﬁcance of SNPs of rs34436714 in the pathogenesis of
IBD, they cannot prove if they drive or not a direct modulation of
the production of blood TNFa.
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